Strahlentherapie des Prostatakarzinoms in der neuen S3-Leitlinie

[1]  M. Piérart,et al.  Duration of androgen suppression in the treatment of prostate cancer. , 2009, The New England journal of medicine.

[2]  T. D. de Reijke,et al.  Salvage radiotherapy in patients with persisting/rising PSA after radical prostatectomy for prostate cancer. , 2009, European journal of cancer.

[3]  T. Wiegel,et al.  Postoperative Radiotherapy for Advanced Prostate Cancer , 2009, Strahlentherapie und Onkologie.

[4]  N. Willich,et al.  Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  T. Wiegel,et al.  Achieving an undetectable PSA after radiotherapy for biochemical progression after radical prostatectomy is an independent predictor of biochemical outcome--results of a retrospective study. , 2009, International journal of radiation oncology, biology, physics.

[6]  E. Messing,et al.  Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. , 2009, The Journal of urology.

[7]  J. Lebesque,et al.  Role of intensity-modulated radiotherapy in reducing toxicity in dose escalation for localized prostate cancer. , 2009, International journal of radiation oncology, biology, physics.

[8]  F. Lohr,et al.  Phantom Measurements to Quantify the Accuracy of a Commercially Available Cone-Beam CT Gray-Value Matching Algorithm Using Multiple Fiducials , 2009, Strahlentherapie und Onkologie.

[9]  S. Fosså,et al.  Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial , 2009, The Lancet.

[10]  Frederik Wenz,et al.  Reduced rectal toxicity with ultrasound-based image guided radiotherapy using BAT™ (B-mode acquisition and targeting system) for prostate cancer , 2008, Strahlentherapie und Onkologie.

[11]  D. Pasquier,et al.  Adjuvant and salvage radiotherapy after prostatectomy for prostate cancer: a literature review. , 2008, International journal of radiation oncology, biology, physics.

[12]  P. Hoskin,et al.  A Phase II study of high-dose-rate afterloading brachytherapy as monotherapy for the treatment of localized prostate cancer. , 2008, International journal of radiation oncology, biology, physics.

[13]  C. Belka,et al.  Adjuvant radiotherapy for patients with locally advanced prostate cancer--a new standard? , 2008, European urology.

[14]  Yoshiya Yamada,et al.  Long-term results of conformal radiotherapy for prostate cancer: impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes. , 2008, International journal of radiation oncology, biology, physics.

[15]  W. Catalona,et al.  Long-term rates of undetectable PSA with initial observation and delayed salvage radiotherapy after radical prostatectomy. , 2008, European urology.

[16]  L. Eapen,et al.  Adjuvant radiotherapy following radical prostatectomy for pathologic T3 or margin-positive prostate cancer: a systematic review and meta-analysis. , 2008, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[17]  Y. Yamada,et al.  Long-term outcome following three-dimensional conformal/intensity-modulated external-beam radiotherapy for clinical stage T3 prostate cancer. , 2008, European urology.

[18]  B. Trock,et al.  Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. , 2008, JAMA.

[19]  Charles R. Thomas,et al.  An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. , 2007, International journal of radiation oncology, biology, physics.

[20]  T. H. van der Kwast,et al.  Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Peter Bownes,et al.  High dose rate brachytherapy in combination with external beam radiotherapy in the radical treatment of prostate cancer: initial results of a randomised phase three trial. , 2007, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[22]  Patrick A. Kupelian,et al.  Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience. , 2007, International journal of radiation oncology, biology, physics.

[23]  M. Parmar,et al.  Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. , 2007, The Lancet. Oncology.

[24]  D. Kuban,et al.  Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  E. Messing,et al.  Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. , 2006, JAMA.

[26]  T. Wilt,et al.  Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer. , 2006, The Cochrane database of systematic reviews.

[27]  R. Laing,et al.  Interstitial low dose rate brachytherapy for prostate cancer--a focus on intermediate- and high-risk disease. , 2006, Clinical oncology (Royal College of Radiologists (Great Britain)).

[28]  Joos V Lebesque,et al.  Acute and late gastrointestinal toxicity after radiotherapy in prostate cancer patients: consequential late damage. , 2006, International journal of radiation oncology, biology, physics.

[29]  J. Damber,et al.  Long-term followup of a randomized study of locally advanced prostate cancer treated with combined orchiectomy and external radiotherapy versus radiotherapy alone. , 2006, The Journal of urology.

[30]  L. Collette,et al.  Radical prostatectomy for locally advanced prostate cancer: results of a feasibility study (EORTC 30001). , 2006, European journal of cancer.

[31]  Joos V Lebesque,et al.  Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  G. Edmundson,et al.  Hypofractionated Conformal HDR Brachytherapy in Hormone Naïve Men with Localized Prostate Cancer , 2006, Strahlentherapie und Onkologie.

[33]  M. Piérart,et al.  Patients at high risk of progression after radical prostatectomy: do they all benefit from immediate post-operative irradiation? (EORTC trial 22911). , 2005, European journal of cancer.

[34]  C. D’Este,et al.  Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. , 2005, The Lancet. Oncology.

[35]  M. Piérart,et al.  Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911) , 2005, The Lancet.

[36]  David E Morris,et al.  Evidence-based review of three-dimensional conformal radiotherapy for localized prostate cancer: an ASTRO outcomes initiative. , 2005, International journal of radiation oncology, biology, physics.

[37]  S. Loening,et al.  High dose rate (HDR) brachytherapy with conformal radiation therapy for localized prostate cancer. , 2005, European urology.

[38]  L. Schour,et al.  High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy's 10-year results. , 2005, International journal of radiation oncology, biology, physics.

[39]  D. Grignon,et al.  Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31. , 2005, International journal of radiation oncology, biology, physics.

[40]  E. Bergstralh,et al.  Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate‐specific antigen testing: 15‐year outcome , 2005, BJU international.

[41]  Qing Guo,et al.  Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  R. Pötter,et al.  GEC/ESTRO-EAU recommendations on temporary brachytherapy using stepping sources for localised prostate cancer. , 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[43]  J. Manola,et al.  6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. , 2004, JAMA.

[44]  B. Norlén,et al.  A systematic overview of radiation therapy effects in prostate cancer , 2004, Acta oncologica.

[45]  H. Lukka,et al.  Baseline staging of newly diagnosed prostate cancer: a summary of the literature. , 2004, The Journal of urology.

[46]  D. Baltas,et al.  3-D Conformal HDR Brachytherapy as Monotherapy for Localized Prostate Cancer , 2004, Strahlentherapie und Onkologie.

[47]  T. Mate,et al.  Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer. , 2004, International journal of radiation oncology, biology, physics.

[48]  J. Blasko,et al.  Ten-year biochemical relapse-free survival after external beam radiation and brachytherapy for localized prostate cancer: the Seattle experience. , 2003, International journal of radiation oncology, biology, physics.

[49]  D. Grignon,et al.  Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  W. Butler,et al.  Does hormonal manipulation in conjunction with permanent interstitial brachytherapy, with or without supplemental external beam irradiation, improve the biochemical outcome for men with intermediate or high‐risk prostate cancer? , 2003, BJU international.

[51]  P. Rubin,et al.  Effect of a short course of neoadjuvant hormonal therapy on the response to subsequent androgen suppression in prostate cancer patients with relapse after radiotherapy: a secondary analysis of the randomized protocol RTOG 86-10. , 2002, International journal of radiation oncology, biology, physics.

[52]  George Starkschall,et al.  Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. , 2002, International journal of radiation oncology, biology, physics.

[53]  Jacques Bernier,et al.  Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial , 2002, The Lancet.

[54]  Jelle O. Barentsz,et al.  Local staging of prostate cancer using magnetic resonance imaging: a meta-analysis , 2002, European Radiology.

[55]  M Bolla,et al.  EAU guidelines on prostate cancer. , 2001, European urology.

[56]  C. Catton,et al.  Adjuvant and salvage radiation therapy after radical prostatectomy for adenocarcinoma of the prostate. , 2001, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[57]  W Cavanagh,et al.  The role of external beam radiotherapy with I-125/Pd-103 brachytherapy for prostate carcinoma. , 2000, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[58]  James A. Purdy,et al.  Three-dimensional conformal therapy or standard irradiation in localized carcinoma of prostate: preliminary results of a nonrandomized comparison. , 2000, International journal of radiation oncology, biology, physics.

[59]  L. Potters,et al.  Examining the role of neoadjuvant androgen deprivation in patients undergoing prostate brachytherapy. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  Michael J. Zelefsky,et al.  Comparison of the 5-Year Outcome and Morbidity of Three-Dimensional Conformal Radiotherapy Versus Transperineal Permanent Iodine-125 Implantation for Early-Stage Prostatic Cancer , 1999 .

[61]  D. Dearnaley,et al.  Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial , 1999, The Lancet.

[62]  J. Forman,et al.  Impact of postprostatectomy prostate-specific antigen nadir on outcomes following salvage radiotherapy. , 1998, Urology.

[63]  M. Altschuler,et al.  The use of clinical parameters in an interactive statistical package to predict pathological features associated with local failure after radical prostatectomy for prostate cancer. , 1993, Clinical performance and quality health care.

[64]  Lei Dong,et al.  Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. , 2008, International journal of radiation oncology, biology, physics.

[65]  A. Cantor,et al.  103Pd brachytherapy versus radical prostatectomy in patients with clinically localized prostate cancer: a 12-year experience from a single group practice. , 2005, Brachytherapy.

[66]  F. Wenz,et al.  Optimierter Einsatz der Strahlentherapie durch IMRT und Präzisionslokalisationsverfahren bei der Behandlung des fortgeschrittenen Prostatakarzinoms , 2004, Der Urologe, Ausgabe A.

[67]  G. Gustafson,et al.  Phase II prospective study of the use of conformal high-dose-rate brachytherapy as monotherapy for the treatment of favorable stage prostate cancer: a feasibility report. , 2001, International journal of radiation oncology, biology, physics.